SanReno,SanReno Therapeutics,信瑞诺,信瑞诺医药,信瑞诺上海

NEWS MORE +

“Start Strong to Win For Kidney Patients”
The Kick Off Meeting of SanReno was successfully held in Shanghai

302023-03

Good news! SanReno officially joins the China Pharmaceutical Innovation and Research Development Association

Recently, the China Pharmaceutical Innovation and Research Development Association (hereinafter referred to “PhIRDA”) voted to approve the application for membership of SanReno Therapeutics (hereinafter referred to as "SanReno") at the 11th plenary meeting of the Council, and SanReno officially became a member of PhIRDA!

102023-01

BIG news！SanReno Global Scientific Advisory Board Established

Shanghai, China -- January 10, 2023 SanReno announced the formal establishment of the Scientific Advisory Board (SAB). As a fast growing biotech company , SanReno is committed to providing innovative treatments and game-changing clinical solutions in nephrology and related therapeutic areas. The Global Scientific Advisory Committee will enhance SanReno’s understanding of science, guide innovative R&D activities, and ensure streamlined corporate strategy.

032021-12

SanReno Therapeutics was Officially Established

SanReno Therapeutics is a joint venture focusing on nephrology and related therapeutic areas. Pivotal bioVenture Partners China jointly established SanReno in China together with Frazier Healthcare Partners, a well-known US life science fund, and Chinook Therapeutics, a clinical-stage biotechnology company. SanReno is led by pharmaceutical veterans from the top tier management team, such as Baxter, Novartis and etc. SanReno is committed to providing world-leading innovative treatments and clinical solutions to create better quality of life for more patients.

 

SanReno Therapeutics

Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. SanReno’s founding investors and partners including Chinook Therapeutics, a leading player in kidney diseases, as well as Pivotal bioVenture Partners China and Frazier Healthcare Partners, both world renown life-science investors. SanReno is committed to the research and development, production and commercialization of drugs in kidney diseases and related therapeutic areas, looks forward to providing innovative clinical solutions to prolong the lives of patients and create a better quality of living for them. Currently, SanReno holds two core assets in the Greater China area and Singapore, including atrasentan (Phase III) and BION-1301 (Phase II).

 

 

Vision

We aspire to become a world-class leading company committed to enable a better life for people suffering from kidney and related diseases and to solve healthcare burden for the community

Mission

We identify the unmet needs for patients with kidney and related diseases, meanwhile we strive and dedicate to discover, develop and deliver life-changing therapies

  • SanReno Owns 2 Best-in-class Programs Targeting Kidney Diseases

    Pre-clinicalPhase IPhase IIPhase III

    • IndicationlgA nephropathy

    • TeritoryGreater China, Singapore

    • PartnerChinook

    • Global statusPhase III

  • SanReno Owns 2 Best-in-class Programs Targeting Kidney Diseases

    Pre-clinicalPhase IPhase IIPhase III

    • IndicationlgA nephropathy

    • TeritoryGreater China, Singapore

    • PartnerChinook

    • Global statusPhase II

  • Atrasentan
  • BION-1301

400-883-0816

info@sanreno.com

Shanghai ● Beijing, China

© 2022 SanReno. All Rights Reserved Terms of UsePrivacy Policy